Clinical Trial

Phase II Clinical Study of BC006 in Patients With Idiopathic Pulmonary Fibrosis

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a multicenter, Phase II clinical study to evaluate the efficacy and safety of BC006 over a 24-week treatment period in patients with idiopathic pulmonary fibrosis (IPF). The study consists of two phases: an open-label safety run-in phase and a double-blind, randomized, placebo-controlled phase.
Protocol Amendment History 1 change
critical Recruitment opened 2026-05-14
Trial Details
NCT Number NCT07447102
Lead Sponsor Dragonboat Biopharmaceutical Company Limited
Conditions Idiopathic Pulmonary Fibrosis (IPF)
Enrollment 96 participants
Start Date 2026-04-27
Primary Completion 2029-04-01 (estimated)
Study Completion 2029-04-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-13